Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.22

€2.22

-7.320%
-0.175
-7.320%
-
 
30.12.25 / Frankfurt WKN: A3EFB5 / Name: Relief Therapeutics Holding / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Relief Therapeutics Holding AG Stock

Relief Therapeutics Holding AG took a tumble today and lost -€0.175 (-7.320%).

Pros and Cons of Relief Therapeutics Holding AG in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

News

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination